Sharemaestro company-news research for Spyre Therapeutics Inc. (SYRE), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest SYRE news and sentiment
Spyre Therapeutics Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
36 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone60/100
→
Published 30-day score52/100
Latest source headline
Spyre Therapeutics launches public stock offering
Investing.com · 05 Oct 2026 20:41
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
36 current stories are mapped specifically to SYRE.
The score uses 12 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.201.
Confidence is 21/100, below the threshold for a firm score.
52/100
News scoreEarly balanced news score
21/100
Confidencethin evidence
98%/100
Company news36 company stories
86/100
Story agreement14/100 difference
News history
Daily score and story count over 30 days
12 Sep27 Sep11 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence4
0.201 after freshness weightingSource breadth100
12 independent publishersCompany relevance98
share tied directly to this companyFreshness18
recency-weighted evidenceAgreement86
how closely stories agreePublisher mix82
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202651USD 85.69-8.0%
02 Oct 202655USD 93.19+8.8%
25 Sep 202649USD 85.69-5.1%
18 Sep 202649USD 90.25-0.4%
11 Sep 202649USD 90.6+1.8%
04 Sep 202647USD 88.98-1.5%
28 Aug 202651USD 90.36-15.1%
21 Aug 202654USD 106.49+2.8%
Provisional evidence
News subjects
What is shaping the score
Market update4223 stories · 64%
Analyst action668 stories · 22%
Earnings633 stories · 8%
Regulatory and legal501 stories · 3%
Balance sheet501 stories · 3%
Source mix
Where the evidence comes from
Stock Titan495 stories · 14%
Moomoo713 stories · 8%
Investing.com383 stories · 8%
simplywall.st573 stories · 8%
GuruFocus503 stories · 8%
TradingView503 stories · 8%
Simply Wall Street512 stories · 6%
Recurring subjects
Subjects appearing most often
Life Sciences19Financial Markets15Finance9Earnings9IPO2Clinical Trials2Biotech2Technology1Fourth Quarter1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
31 Jul50 neutral11 Oct 18:46
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 11 Oct 18:46 | 51 | +0 | 22/100 (-14) | 34 (-7) | Provisional |
| 05 Oct 23:59 | 51 | -1 | 36/100 (-2) | 41 (-1) | Measured |
| 04 Oct 23:59 | 52 | +1 | 38/100 (-2) | 42 (-5) | Measured |
| 03 Oct 23:59 | 51 | -4 | 40/100 (+5) | 47 (+2) | Measured |
| 02 Oct 23:59 | 55 | -1 | 35/100 (-3) | 45 (+2) | Provisional |
| 01 Oct 23:59 | 56 | +3 | 38/100 (+8) | 43 (+6) | Provisional |
| 30 Sep 23:59 | 53 | +1 | 30/100 (+2) | 37 (+1) | Provisional |
| 28 Sep 23:59 | 52 | +3 | 28/100 (+10) | 36 (-11) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 36 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Analyst action5 stories
0.0%46.9%
Market update8 stories
27.7%0.0%
Earnings2 stories
2.0%23.4%
Each side uses the same scale: 0–46.9% of the retained directional evidence.
Where the influence comes from
34.5%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Is Positive Trial Data Altering The Investment Case For Spyre Therapeutics (SYRE)?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 21 Sep 2026 07:00
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests
On September 8, Spyre Therapeutics (NASDAQ:SYRE) announced that SPY003, its anti-IL-23 antibody, hit its primary endpoint in Part A of the Phase 2 SKYLINE trial, posting a 10.0-point reduction in Robart's Histopathology Index score at Week 12 with a p-value below 0.0001. That result matte…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
On September 8, Spyre Therapeutics (NASDAQ:SYRE) announced that SPY003, its anti-IL-23 antibody, hit its primary endpoint in Part A of the Phase 2 SKYLINE trial, posting a 10.0-point reduction in Robart's Histopathology Index score at Week 12 with a p-value below 0.0001. That result matters because it closes out a run of three straight readouts. Spyre has now shown proof-of-concept for all three molecules behind its inflammatory bowel disease combination strategy in a five-month stretch.COPT Defense (CDP) Keeps Leasing Ahead Of Its Own Targets Three Shots, Three Makes The pattern across SPY001
- Published
- 17 Sep 2026 07:04
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechClinical TrialsEarningsFourth QuarterIPOLife Sciences
43/100 tone
2% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 16 Sep 2026 19:47
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 32/100
- 30-day weight
- 2% of directional evidence · 25.0d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
60/100 tone
<0.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 14 Sep 2026 07:27
- News subject
- Market update
- Why this score
- Positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- <0.1% of directional evidence · 27.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Will Phase 2 UC Data Change Spyre Therapeutics Stock Narrative
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 13 Sep 2026 01:45
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
57/100 tone
<0.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 11 Sep 2026 22:42
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- <0.1% of directional evidence · 29.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
SYRE news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 127 older SYRE headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to SYRE, but the headline and available text are not mainly about Spyre Therapeutics Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of SYRE sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.